Evobrutinib is the First and Only BTK Inhibitor for Multiple Sclerosis
Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology Annual Meeting showing that the investigational Bruton’s tyrosine kinase inhibitor evobrutinib significantly reduced blood neurofilament light chain evels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis (MS).